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Abstract
Background: Hepatitis C virus (HCV), a member of the Flaviviridae family of viruses, is a major cause of chronic
hepatitis, liver cirrhosis and hepatocellular carcinoma. Currently, the only treatment available consists of a
combination of Pegylated interferon alpha (INF-a) and ribavirin, but only half of the patients treated show a
sufficient antiviral response. Thus there is a great need for the development of new treatments for HCV infections.
RNA interference (RNAi) represents a new promising approach to develop effective antiviral drugs and has been
extremely effective against HCV infection.
Results: This study was design to assess or explore the silencing effect of small interference RNAs (siRNAs) against
full length HCV particles of genotype 1a. In the present study six 21-bp siRNAs were designed against different
regions of HCV structural genes (Core, E1 and E2). Selected siRNAs were labeled as Csi 301, Csi 29, E1si 52, E1si 192,
E2si 86 and E2si 493. Our results demonstrated that siRNAs directed against HCV core gene showed 70% reduction
in viral titer in HCV infected liver cells. Moreover, siRNAs against E1 and E2 envelop genes showed a dramatic
reduction in HCV viral RNA, E2si 86 exhibited 93% inhibition, while E1si 192, E2si 493 and E1si 52 showed 87%,
80%, and 66% inhibition respectively. No significant inhibition was detected in cells transfected with the negative
control siRNA.
Conclusion: Our results suggested that siRNAs targeted against HCV structural genes efficiently silence full length
HCV particles and provide an effective therapeutic option against HCV infection.
Background
HCV was identified in 1989 as the leading pathogen for
non-A, non-B viral hepatitis [1]. HCV is an enveloped
positive-single stranded RNA virus 9.6 kb in length con-
sisting of structural (Core, E1, E2 and possibly p7) pro-
teins and nonstructural (NS2, NS3, NS4A, NS4B, NS5A
and NS5B) proteins [2,3]. HCV Core is known as the
inducer of steatosis, oxidative stress and liver cancer [4].
E1 and E2 are involved in virus attachment with the
cells and are considered to be the first viral proteins
come in contact with the cells [5]. An estimated more
than 170 million individuals worldwide have been
chronically infected, while 3-4 million new infections
believed to occur each year [6]. Many infected
individuals develop liver damage with an increased risk
of progression to fibrosis, cirrhosis, and liver cancer [7].
Currently the standard therapy for HCV is pegylated
interferon (PEG-INF) with nucleoside analog ribavirin
(RBV). This therapy achieves 50% sustained virological
response (SVR) for genotype 1, which is the most preva-
lent form of the virus in the United States, Western
Europe and Japan. SVR is 80% for genotype 2 & 3,
which is the most prevalent genotype in Pakistan [8-10].
A sustained viral response occurs when there is no trace
of HCV RNA present in the patient’s blood immediately
after treatment and also six months post-treatment. As
pegylated interferon is expensive, standard interferon is
still the main therapy for HCV treatment in under
developed countries. Studies showed that current thera-
pies are costly and cause a variety of side effects, includ-
ing irritability, headache, flu-like symptoms, anemia,
depression and gastrointestinal symptoms [10]. Low
response rates and the significant side effect burden of
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more effective anti-HCV agents, especially for treatment
of patients infected with genotype 1a.
RNA interference (RNAi), a post-transcriptional regu-
lation mechanism, is initiated by small interfering RNAs
(siRNAs) of 21-23 nucleotides, which are incorporated
into a multi-protein complex commonly known as the
RNA-induced silencing complex (RISC), leading to
sequence-specific degradation of target mRNA recog-
nized by the antisense strand of the siRNA [11-16].
RNAi was first discovered in the nematode worm Cae-
norrhabditis elegans [11], but it is present in many other
organisms such as Drosophila, certain parasitic protozoa,
and vertebrates [17,18]. Small interference RNA (siRNA)
is a valuable tool to inhibit the expression of a target
gene in a sequence-specific manner, and may be used
for functional genomics, target validation and therapeu-
tic purposes. The difference between antisense
approaches and conventional drugs is that the conven-
tional drugs bind to proteins and thereby modulate their
function whereas antisense agents act at the mRNA
level, preventing its translation into protein [19,20]. siR-
NAs can be used as a potential therapeutic agents
against HCV because HCV replication takes place in the
cytoplasm of liver cells without integration into the host
genome. Moreover, its genome functions both as an
mRNA and as a replication template. Several reports
demonstrated potent RNAi activity against HCV in sub-
genomic replicon and infection [21-23]. Synthetic or
vector based siRNAs targeted against 5’ untranslated
region (UTR), HCV core, NS3, NS4B and NS5B were
found to be effective in reducing viral replication and
infection [22-26].
The present study was undertaken to study the effect
of siRNAs directed against the structural genes of the
HCV genotype 1a in HCV infected liver cells. It demon-
strates that the RNAi-mediated silencing of the HCV
full length viral particle may be one of the important
therapeutic opportunities against HCV 1a genotype.
Materials and methods
Serum Sample Collection
HCV-1a patient’ss e r u ms a m p l e su s e di nt h i si n v e s t i g a -
tion were obtained from the CAMB (Center for Applied
Molecular Biology) diagnostic laboratory, Lahore, Paki-
stan. Serum samples were stored at -80°C prior to viral
inoculation experiments. Quantification and genotype
was assessed by CAMB diagnostic laboratory, Lahore,
Pakistan. Patient’s written consent and approval for this
study was obtained from institutional ethics committee.
siRNAs designing
Small interfering RNA oligonucleotides against HCV
core, envelop protein (E1 and E2) and P7 genes were
designed to the most conserved target region of these
genes using the Ambion’s siRNA design tool http://
www.ambion.com/techlib/misc/siRNA_finder.html. The
designed siRNAs against HCV core, envelop protein (E1
and E2) and P7 genes were synthesized using Silencer
siRNA construction kit according to the manufacturer’s
instruction (Ambion, USA).
Cell line
The Huh-7 cell line was compassionately offered by Dr.
Zafar Nawaz (Biochemistry and Molecular Biology
Department, University of Miami, USA). Huh-7 cells
were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum &
100 IU/ml penicillin & 100 μg/ml streptomycin, at 37°C
in an atmosphere of 5% CO2.
MTT assay for toxicity
To investigate cellular toxicity, 2 × 10
4 cells/well was
plated into 96-well plates. After 24 h, different concen-
trations of siRNAs were added and the plate was sealed
and kept at 37°C in an atmosphere of 5% CO
2 for 24 h.
After the siRNAs treatment were over, removed the
media and siRNAs. About 100 μl fresh media and 20 μl
of MTT solution (5 mg/ml in PBS) were added to all
wells in Columns 1-11. Wrapped the plate in aluminum
foil and incubated for 3-4 h at 37°C. Media was carefully
removed and added 100 μl of DMSO to dissolve the for-
mazan crystals in Columns 1-11. MTT formazan pro-
duct was determined by measuring absorbance with an
enzyme-linked immunosorbent assay (ELISA) plate
reader at a test wavelength of 570 nm and a reference
wavelength of 620 nm.
Cell viability was obtained using the following equa-
tion:
Percent cell viability =

Test 570nm − 620nm/Control 570nm − 620nm

*10
Silencing effect of siRNAs in serum infected liver cells
Huh-7 cell line was used to establish the in-vitro repli-
cation of HCV. A similar protocol was used for viral
inoculation as established by Zekari et al. 2009 [27] and
El-Awardy et al. 2006 [28]. High viral titer >1 × 10
8 IU/
ml from HCV-1a patient’s was used as principle inocu-
lum in these experiments. Huh-7 cells were maintained
in 6-well culture plates to semi-confluence, washed
twice with serum-free medium, then inoculated with
500 μl( 5×1 0
7IU/well) and 500 μl serum free media.
Cells were maintained overnight at 37°C in 5% CO2.
Next day, adherent cells were washed three times with 1
× PBS, complete medium was added and incubation was
continued for 48 h. Cells were harvested and assessed
for viral RNA quantification by Real Time PCR. To ana-
lyze the effect of siRNAs on HCV infection, serum
infected Huh-7 cells were again seeded after three days
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absence of siRNAs and grown to 80% confluence. After
48 h, cells and total RNA was isolated by using Gentra
RNA isolation kit (Gentra System Pennsylvania, USA)
according to the manufacturer’s instructions. Briefely,
cells were lysed with cell lysis solution containing 5 μl
internal control (Sacace Biotechnologies Caserta, Italy).
RNA pallet was solubilized in 1% DEPC (Diethyl pyro-
carbonate treated water). HCV RNA quantifications
were determined by Real Time PCR Smart Cycler II sys-
tem (Cepheid Sunnyvale, USA) using the Sacace HCV
quantitative analysis kit (Sacace Biotechnologies Caserta,
Italy) according to the manufacturer’s instructions.
Formula for the calculation of HCV RNA concentration
Following formula was used to calculate the concentra-
tion HCV RNA of each sample.
Cy3STD/Res
Fam. STD/Res
× coefﬁcient IC = IU HCV/mL
IC = internal control, which is specific for each lot.
Statistical Analysis
All statistical analysis was done using SPSS software
(version 11.0, SPSS Inc). Data is presented as mean ±
SE. Numerical data was analyzed using student’st - t e s t
and ANOVA. P value < 0.05 was considered statistically
significant.
Results
Toxicological analysis of siRNAs
Before starting the antiviral screening against HCV, toxi-
cological effect of siRNAs were determined through
MTT cell proliferation assay. The MTT substance is
reduced by mitochondrial succinic dehydrogenases in
living cells to purple formazan crystals that are not solu-
ble in aqueous water. The absorption of dissolved for-
m a z a ni nt h ev i s i b l er e g i o nc o r r e l a t e sw i t ht h en u m b e r
of alive cells [29]. Figure 1 shows cytotoxicity analysis of
siRNAs and demonstrates that Huh7 cells viability is
unaffected at a concentration of 20 μM (Figure 1).
Silencing effect of siRNAs on liver infected cells
The ability of siRNAs to inhibit HCV replication and
infection was evaluated by designing and constructing
siRNAs against different sites of HCV structural genes
having genotype1a (Core, E1 and E2). siRNAs targeting
sites were selected in regions conserved among different
samples. Selected siRNAs were labeled as Csi 301, Csi
29, E1si 52, E1si 192, E2si 86 and E2si 493. Negative
control siRNA (scrambled siRNA) with the same
nucleotide composition as the experimental siRNA
which lacks significant sequence homology to the HCV
and human genome was designed (Table 1). The results
indicate that siRNAs targeting HCV structural genes
have the ability to inhibit the whole virus of 1a genotype
in serum infected liver cells. The effect of gene-specific
siRNAs against the whole virus was evaluated in serum-
infected Huh-7 cells by measuring reduction in the
HCV RNA titer. Real-time PCR results showed that
core siRNAs (Csi 301 and Csi 29) reduced HCV-1a
RNA level up to 70% (Figure 2). siRNAs against E1 and
E2 envelop genes showed a dramatic reduction in HCV
v i r a lR N A ,E 2 s i8 6s h o w e dam a x i m u mi n h i b i t i o no f
about 93%, while E1si 192, E2si 493 and E1si 52 showed
87%, 80%, and 66% inhibition respectively (Figure 3).
Together, these data suggest a negative impact of che-
mically synthesized Core and envelop genes siRNAs on
HCV replication and infection that could be used for
the down regulation of the whole viral particle of HCV
la genotype. This result was in accordance with Zekri et
Figure 1 Toxicity of siRNAs through MTT cell proliferation
assay. Huh-7 cells were plated at the density of 2 × 10
4 in 96 well
plates. After 24 h cells were treated with different concentrations of
siRNAs and control consisted of solvent in which siRNAs dissolved.
After 24 h incubation period add MTT solution to all wells and
incubated for 3-4 h at 37°C. Viable cells convert MTT to purple
formazan crystal. Added DMSO to dissolve the formazan crystals
and read absorbance at 570 nm and 620 nm.
Table 1 Sequence of siRNA oligonucleotides directed
against structural genes of HCV 1a genotype
SN siRNAs Name Sequence 5’-3’
1 Csi 29-antisense AAACCAAACGTAACACCAACCCCTGTCTC
2 Csi 29-sense AAGGTTGGTGTTACGTTTGGTCCTGTCTC
3 Csi 301-antisense AAGGTCATCGATACCCTTACGCCTGTCTC
4 Csi 301-sense AACGTAAGGGTATCGATGACCCCTGTCTC
5 E1si 52-antisense AACTCGAGTATTGTGTACGAGCCTGTCTC
6 E1si 52-sense AACTCGTACACAATACTCGAGCCTGTCTC
7 E1si 192-antisense AACGCAGCTTCGACGTCATATCCTGTCTC
8 E1si 192-sense AAATATGACGTCGAAGCTGCGCCTGTCTC
9 E2si 86-antisense AACTGATCAACACCAACGGCACCTGTCTC
10 E2si 86-sense AATGCCGTTGGTGTTGATCAGCCTGTCTC
11 E2si 493-antisense AATTGGTTCGGTTGTACCTGGCCTGTCTC
12 E2si 493-sense AACCAGGTACAACCGAACCAACCTGTCTC
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siRNAs against 5’UTR on 3rd day of post-transfection.
Discussion
HCV is a leading cause of acute and chronic hepatitis
which can eventually lead to permanent liver damage,
hepatocellular carcinoma and death. Currently, there is
no vaccine available for prevention of HCV infection
due to high degree of strain variation. The only therapy
available is a combination of interferon and ribavirin,
which cure only 50% of patients having genotype 1a.
RNA interference (RNAi) represents a new promising
approach to develop effective antiviral drugs against
HCV. In order to identify potent anti-HCV agents,
many investigators design and test multiple oligonucleo-
tides that target different sites and regions of the target
mRNA and many of them show desired results [30].
The underlying mechanism of siRNA-mediated gene
silencing is still unknown in mammalian cells; it could
interfere with RNA stability and/or translation or, alter-
natively, transcription. In cultured mammalian cell lines,
chemically synthesized siRNAs can be introduced into
cells when formulated with lipophilic reagents [31].
Longer dsRNAs (50 bp) have a more broad effect in
mammalian somatic cells, resulting in general arrest of
protein synthesis through interferon response and also
protein kinase activation. In contrast, shorter siRNAs of
21-23 nt have a more specific effect, inducing up to 90%
suppression of specific mRNAs both in vitro and in vivo
[12,22]. Due to its high suppression efficiency and
sequence specificity up to a single nucleotide resolution
[13] has encouraged the development of RNAi-based
therapeutic models for possible use in viral infections i.
e. HIV-1 [32], HBV [22], HCV [22], respiratory viruses
[33] and cancer i.e. K-ras [34], PI 3-kinase [31]. The
HCV genome is a positive-sense single-stranded RNA
that functions as both a messenger RNA and replication
template via a negative-strand intermediate, making it
an attractive target for the study of RNA interference.
A potential problem that may arise in RNAi based
approach is the error prone nature of HCV genome
with generation of quasispecies during chronic HCV
infection but this problem can be overcome by design-
ing siRNAs against highly conserved region of HCV
[35-37]. Several reports demonstrated that RNAi, effi-
ciently inhibits viral replication and infection by target-
ing 5’U T R ,C o r e ,E 1 ,E 2 ,N S 3 ,N S 4 ba n dN S 5 b
sequences as alternative anti-HCV strategies [23,25,
35,38-40]. Two different groups used siRNA against
Core gene of HCV 1a and 1b genotype and observed
60% and 80% reduction in mRNA and protein expres-
sion respectively [40,41]. A study demonstrated that siR-
NAs targeted against E2, NS3 and NS5B regions
effectively inhibit core gene expression [41] and Kim et
al., 2006, has designed siRNAs against HCV 1b and 1a
genome to explore the silencing of structural genes and
showed significantly less expression in a dose-dependent
manner. In the present study, six different siRNAs were
designed, with GC content of 35-50%, targeting struc-
tural genes of HCV 1a genotype.
The plaque assay is the most important procedure in
virology to measure virus infectious titers by visualizing
the viral-induced cytopathic effect. However, plaque
assay for HCV is not available because HCV is non-
cytopathic and detection of HCV-infected cells com-
monly rely on visualization of the infected cells by
immunostaining of HCV proteins [42], western blotting
Figure 2 Silencing effect of core specific siRNAs against full
length viral particles of HCV 1a genotype. Huh-7 cells were
infected with high titer sera sample from HCV-1a patients (S1a) to
establish in vitro cell culture model of HCV-1a, cells were
maintained overnight at 37°C in 5% CO2 for three days. Cells were
harvested after siRNA treatment 48 hrs post transfection and
intracellular HCV RNA levels were quantified by Real Time PCR. Data
is expressed as percentage of HCV survival in cells. S1a means
control consisted of HCV serum of 1a genotype) and SC means
scrambled siRNA. Error bars indicate, mean S.D p < 0.05 verses S1a.
Figure 3 Silencing effect of HCV E1 and E2 specific siRNAs
against full length viral particles of HCV 1a genotype. Huh-7
cells were infected with high titer sera sample from HCV-1a patients
(S1a) to establish in vitro cell culture model of HCV-1a, cells were
maintained overnight at 37°C in 5% CO2 for three days. Cells were
harvested after siRNA treatment 48 hrs post transfection and
intracellular HCV RNA levels were quantified by Real Time PCR. Data
is expressed as percentage of HCV survival in cells. S1a means
control consisted of HCV serum of 1a genotype) and SC means
scrambled siRNA. Error bars indicate, mean S.D p < 0.05 verses S1a.
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HCV replication in serum-infected liver cell lines, which
mimics the naturally occurring HCV infection in
humans [28,43,44]. In this study, Huh-7 cells were
infected with native viral particles from HCV-genotype-
1a positive serum, using the same protocol as described
by El-Awady et al., and Zekri et al. [27,28]. siRNAs
against HCV-1a structural genes used in the present
study were screened against HCV-serum-infected Huh-7
cells. An exciting finding of this study was a decrease in
the HCV viral titer to a maximum of 93% after treat-
ment with gene-specific siRNAs (E1si 88). siRNAs
against HCV core gene (Csi 301, Csi 29) showed up to
70% inhibition in the viral titer of HCV 1a genotype
(Figure 2). Similarly siRNAs directed against HCV
envelop proteins (E1si 192, E2si 493 and E1si 52)
showed 87%, 80%, and 66% inhibition in the viral titer
of genotype 1a respectively (Figure 3). These results are
in agreement with previous studies, which have sug-
gested that siRNA is the most efficient nucleic-acid-
based antiviral approach that can be utilized to degrade
the HCV genome in infected cells.
In conclusion, current therapy for HCV infection is
mainly the combination use of interferon and ribavirin,
but only about half of the treated patients obtain a sus-
tained antiviral response. Our data suggest that siRNAs
targeting HCV structural genes can target viral RNA in
infected cells, potentially providing an efficient therapeu-
tic option against HCV infection.
Abbreviations
HCV: Hepatitis C virus; PEG-INF: Pegylated interferon; SVR: Sustained
Virological Response; siRNAs: Small interference RNAs; Huh-7: Human
Hepatoma Cell line.
Acknowledgements
Financial support by Higher Education Commission Pakistan is highly
acknowledged.
Author details
1Division of Molecular Medicine, National Centre of Excellence in Molecular
Biology, University of the Punjab, Lahore, Pakistan.
2Department of Human
Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The
Netherlands.
3Applied and Functional Genomics Laboratory, National Center
of Excellence in Molecular Biology, University of Punjab, Lahore, Pakistan.
4Allama Iqbal Medical College, Allama Shabir Ahmad Usmani Road, Lahore,
Pakistan.
Authors’ contributions
MA, UAA and MI contributed equally in lab work and manuscript write up.
MTS, TJ and SDR helped me in writing the manuscript. SH and SRD was the
principal investigator and provides all facilities to complete this work. All the
authors read and approved the final manuscript.
Authors’ information
Muhammad Ansar (PhD Scholar), Usman Ali Ashfaq (PhD Molecular Biology),
Imran shahid (M Phil Molecular Biology), Muhammad Tahir Sarwar (PhD
scholar), Tariq Javed (M. Phil pharmaceutical chemistry, Sidra Rehman (MSc
Chemistry), Sajida Hassan (PhD Molecular Biology) and Sheikh Riazuddin
(PhD molecular Biology and Dean Post graduate study at Allama Iqbal
medical college, Lahore
Competing interests
The authors declare that they have no competing interests.
Received: 28 January 2011 Accepted: 2 May 2011 Published: 2 May 2011
References
1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation
of a cDNA clone derived from a blood-borne non-A, non-B viral
hepatitis genome. Science 1989, 244:359-362.
2. Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM: Processing in the
hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-
specific products with different C termini. J Virol 1994, 68:5063-5073.
3. Reed KE, Rice CM: Overview of hepatitis C virus genome structure,
polyprotein processing, and protein properties. Curr Top Microbiol
Immunol 2000, 242:55-84.
4. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T,
Miyazawa T, Ishibashi K, Horie T, et al: Oxidative stress in the absence of
inflammation in a mouse model for hepatitis C virus-associated
hepatocarcinogenesis. Cancer Res 2001, 61:4365-4370.
5. Liu Q, Tackney C, Bhat RA, Prince AM, Zhang P: Regulated processing of
hepatitis C virus core protein is linked to subcellular localization. J Virol
1997, 71:657-662.
6. WHO: World Health Organization. Department of Measurement and
Health Information. 2004 [http://www.who.int/healthinfo/statistics/
bodgbddeathdalyestimates.xls].
7. Memon MI, Memon MA: Hepatitis C: an epidemiological review. J Viral
Hepat 2002, 9:84-100.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M,
Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon
alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for
initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001,
358:958-965.
9. Di Bisceglie AM, Hoofnagle JH: Optimal therapy of hepatitis C. Hepatology
2002, 36:S121-127.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr,
Haussinger D, Diago M, Carosi G, Dhumeaux D, et al: Peginterferon alfa-2a
plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002,
347:975-982.
11. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and
specific genetic interference by double-stranded RNA in Caenorhabditis
elegans. Nature 1998, 391:806-811.
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes
of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 2001, 411:494-498.
13. Elbashir SM, Lendeckel W, Tuschl T: RNA interference is mediated by 21-
and 22-nucleotide RNAs. Genes Dev 2001, 15:188-200.
14. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T: Functional
anatomy of siRNAs for mediating efficient RNAi in Drosophila
melanogaster embryo lysate. Embo J 2001, 20:6877-6888.
15. Hannon GJ: RNA interference. Nature 2002, 418:244-251.
16. Cullen BR: RNA interference: antiviral defense and genetic tool. Nat
Immunol 2002, 3:597-599.
17. Sharp PA: RNA interference–2001. Genes Dev 2001, 15:485-490.
18. Tuschl T: RNA interference and small interfering RNAs. Chembiochem
2001, 2:239-245.
19. Scherer LJ, Rossi JJ: Approaches for the sequence-specific knockdown of
mRNA. Nat Biotechnol 2003, 21:1457-1465.
20. Sahu NK, Shilakari G, Nayak A, Kohli DV: Antisense technology: a selective
tool for gene expression regulation and gene targeting. Curr Pharm
Biotechnol 2007, 8:291-304.
21. Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S,
Landthaler M, Landgraf P, Kan S, Lindenbach BD, et al: Cellular cofactors
affecting hepatitis C virus infection and replication. Proc Natl Acad Sci
USA 2007, 104:12884-12889.
22. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA: RNA
interference in adult mice. Nature 2002, 418:38-39.
23. Kapadia SB, Brideau-Andersen A, Chisari FV: Interference of hepatitis C
virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA
2003, 100:2014-2018.
24. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, Sun J, Heathcote J,
Rice CM, Edwards AM, McGilvray ID: Silencing of USP18 potentiates the
Ansar et al. Virology Journal 2011, 8:203
http://www.virologyj.com/content/8/1/203
Page 5 of 6antiviral activity of interferon against hepatitis C virus infection.
Gastroenterology 2006, 131:1584-1591.
25. Wilson JA, Jayasena S, Khvorova A, Sabatinos S, Rodrigue-Gervais IG, Arya S,
Sarangi F, Harris-Brandts M, Beaulieu S, Richardson CD: RNA interference
blocks gene expression and RNA synthesis from hepatitis C replicons
propagated in human liver cells. Proc Natl Acad Sci USA 2003,
100:2783-2788.
26. Takigawa Y, Nagano-Fujii M, Deng L, Hidajat R, Tanaka M, Mizuta H,
Hotta H: Suppression of hepatitis C virus replicon by RNA interference
directed against the NS3 and NS5B regions of the viral genome.
Microbiol Immunol 2004, 48:591-598.
27. Zekri AR, Bahnassy AA, El-Din HM, Salama HM: Consensus siRNA for
inhibition of HCV genotype-4 replication. Virol J 2009, 6:13.
28. el-Awady MK, Tabll AA, el-Abd YS, Bahgat MM, Shoeb HA, Youssef SS, Bader
el-Din NG, Redwan el RM, el-Demellawy M, Omran MH, et al: HepG2 cells
support viral replication and gene expression of hepatitis C virus
genotype 4 in vitro. World J Gastroenterol 2006, 12:4836-4842.
29. Mosmann T: Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Methods
1983, 65:55-63.
30. Khaliq S, Khaliq SA, Zahur M, Ijaz B, Jahan S, Ansar M, Riazuddin S, Hassan S:
RNAi as a new therapeutic strategy against HCV. Biotechnol Adv 28:27-34.
31. Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA: Specific inhibition of
gene expression by small double-stranded RNAs in invertebrate and
vertebrate systems. Proc Natl Acad Sci USA 2001, 98:9742-9747.
32. Shin D, Lee H, Kim SI, Yoon Y, Kim M: Optimization of linear double-
stranded RNA for the production of multiple siRNAs targeting hepatitis
C virus. Rna 2009, 15:898-910.
33. Bitko V, Musiyenko A, Shulyayeva O, Barik S: Inhibition of respiratory
viruses by nasally administered siRNA. Nat Med 2005, 11:50-55.
34. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of
short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
35. Prabhu R, Vittal P, Yin Q, Flemington E, Garry R, Robichaux WH, Dash S:
Small interfering RNA effectively inhibits protein expression and
negative strand RNA synthesis from a full-length hepatitis C virus clone.
J Med Virol 2005, 76:511-519.
36. Wilson JA, Richardson CD: Hepatitis C virus replicons escape RNA
interference induced by a short interfering RNA directed against the
NS5b coding region. J Virol 2005, 79:7050-7058.
37. Watanabe T, Umehara T, Yasui F, Nakagawa S, Yano J, Ohgi T, Sonoke S,
Satoh K, Inoue K, Yoshiba M, Kohara M: Liver target delivery of small
interfering RNA to the HCV gene by lactosylated cationic liposome. J
Hepatol 2007, 47:744-750.
38. Seo MY, Abrignani S, Houghton M, Han JH: Small interfering RNA-
mediated inhibition of hepatitis C virus replication in the human
hepatoma cell line Huh-7. J Virol 2003, 77:810-812.
39. Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, Yi L,
Kurosaki M, Taira K, Watanabe M, Mizusawa H: Inhibition of intracellular
hepatitis C virus replication by synthetic and vector-derived small
interfering RNAs. EMBO Rep 2003, 4:602-608.
40. Kim M, Shin D, Kim SI, Park M: Inhibition of hepatitis C virus gene
expression by small interfering RNAs using a tri-cistronic full-length viral
replicon and a transient mouse model. Virus Res 2006, 122:1-10.
41. Liu M, Ding H, Zhao P, Qin ZL, Gao J, Cao MM, Luan J, Wu WB, Qi ZT: RNA
interference effectively inhibits mRNA accumulation and protein
expression of hepatitis C virus core and E2 genes in human cells. Biosci
Biotechnol Biochem 2006, 70:2049-2055.
42. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF,
Uprichard SL, Wakita T, Chisari FV: Robust hepatitis C virus infection in
vitro. Proc Natl Acad Sci USA 2005, 102:9294-9299.
43. Lazaro CA, Chang M, Tang W, Campbell J, Sullivan DG, Gretch DR, Corey L,
Coombs RW, Fausto N: Hepatitis C virus replication in transfected and
serum-infected cultured human fetal hepatocytes. Am J Pathol 2007,
170:478-489.
44. Buck M: Direct infection and replication of naturally occurring hepatitis C
virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures.
PLoS One 2008, 3:e2660.
doi:10.1186/1743-422X-8-203
Cite this article as: Ansar et al.: Inhibition of full length Hepatitis C Virus
particles of 1a genotype through small interference RNA. Virology
Journal 2011 8:203.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ansar et al. Virology Journal 2011, 8:203
http://www.virologyj.com/content/8/1/203
Page 6 of 6